CCA
FOLD

Cygnus Capital Advisors’s Amicus Therapeutics FOLD Stock Holding History

Cygnus Capital Advisors’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$59 Hold
4,082
– – 0.04% 69
2025
Q4 		$58 Buy
+4,082
New +$40.1K 0.04% 64

Other funds holding FOLD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Cygnus Capital Advisors's FOLD Position: Q1 2026 in Review

Cygnus Capital Advisors held its Amicus Therapeutics (FOLD) position steady in Q1 2026 at 4,082 shares worth $59. The position accounts for 0.04% of the portfolio, ranked #69.

Cygnus Capital Advisors first reported a position in FOLD in Q4 2025 and has held it in 2 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Cygnus Capital Advisors held 4,082 shares of Amicus Therapeutics worth $59 as of Q1 2026.
  • Cygnus Capital Advisors left its Amicus Therapeutics share count unchanged in Q1 2026.
  • Amicus Therapeutics made up 0.04% of Cygnus Capital Advisors's portfolio in Q1 2026, its #69 holding.
  • Cygnus Capital Advisors first reported a position in Amicus Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Cygnus Capital Advisors's 13F filing for Q1 2026, filed 13 May 2026.